In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

ESC Clinical Practice Guidelines

This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published since the 2019 version, up until 31 March 2025.

The Task Force also considered and discussed: combination therapy with high-dose statin plus ezetimibe and intensification of lipid-lowering therapy during the index hospitalization for patients presenting with acute coronary syndrome (ACS), as well as new data on lipoprotein(a) [Lp(a)] as a risk modifier.

Only results that would lead to new or changed Class I/IIa or Class III recommendations were selected for inclusion in Recommendation Tables.

Coronary Artery Disease (Chronic)
Cardiovascular Disease in Primary Care
Rehabilitation and Sports Cardiology
Basic Science
Treatment
Hypertension
Lipids
Risk Factors and Prevention
Cardiovascular Pharmacotherapy

Main resources

Scientific Presentation at ESC Congress 2025

Follow the session live, or catch the replay.

Watch now